Trevena (TRVN) - P/S ratio

P/S ratio as of February 2025 (TTM): 1.69

According to Trevena's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -0.0586. At the end of 2024 the company had a P/S ratio of 4.20.

P/S ratio history for Trevena from 2014 to 2024

PS ratio at the end of each year

Year	P/S ratio	Change
2024	4.20	62.95%
2023	2.58
2022	N/A	-100%
2021	169	51.49%
2020	112	-95.63%
2019	> 1000	41281.99%
2018	6.18
2017	N/A	-100%
2016	82.1	-3.85%
2015	85.3
2014	N/A

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Amgen AMGN	4.71	178.94%	🇺🇸 USA
Cytokinetics CYTK	> 1000	105,516.63%	🇺🇸 USA
Cara Therapeutics CARA	0.1868	-88.94%	🇺🇸 USA
Merck MRK	3.97	134.93%	🇺🇸 USA
Arena Pharmaceuticals ARNA	N/A	N/A	🇺🇸 USA
AcelRx Pharmaceuticals ACRX	22.4	1,225.84%	🇺🇸 USA
Flexion Therapeutics FLXN	N/A	N/A	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Trevena (TRVN)

P/S ratio as of February 2025 (TTM): 1.69